United Therapeutics Corpo... (UTHR)
undefined
undefined%
At close: undefined
361.81
0.12%
After-hours Dec 13, 2024, 05:19 PM EST

Company Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).

It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag.

The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

United Therapeutics Corporation
United Therapeutics Corporation logo
Country United States
IPO Date Jun 17, 1999
Industry Biotechnology
Sector Healthcare
Employees 1,168
CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.

Contact Details

Address:
1040 Spring Street
Silver Spring, Maryland
United States
Website https://www.unither.com

Stock Details

Ticker Symbol UTHR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001082554
CUSIP Number 91307C102
ISIN Number US91307C1027
Employer ID 52-1984749
SIC Code 2834

Key Executives

Name Position
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & Chief Executive Officer
James C. Edgemond Chief Financial Officer & Treasurer
Michael I. Benkowitz President & Chief Operating Officer
Dewey Steadman C.F.A. Head of Investor Relations
Dr. Leigh Peterson Executive Vice President of Product Development & Xenotransplantation
Gil Golden Senior Vice President & Chief Medical Officer
Holly Hobson Associate Vice President of Human Resources
Kevin T. Gray Senior Vice President of Strategic Operations & Logistics
Patrick Poisson Executive Vice President of Technical Operations
Paul A. Mahon J.D. Executive Vice President, General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Dec 10, 2024 4 Filing
Dec 06, 2024 4 Filing
Dec 03, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 22, 2024 4 Filing
Nov 19, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 12, 2024 4 Filing
Nov 08, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...